Find an expert

I am a basic science researcher with training in cell biology, genetics and research translation. My research investigates the female reproductive system by focusing on the contribution of individual cells. I aim to understand the influence of genetic architecture, differentiation and maturation on these individual cells and how this contributes to changes in the microenvironment that can contribute to disease initiation and progression.

After the completion of my PhD in 2008 at the University of Queensland, I undertook post-doctoral studies at the University of Bern, Department of Biomedical Research (DBMR), focusing on endometriosis, ovarian and endometrial cancer. I curated patient samples from clinical research trials to investigate inflammatory and metabolic components of reproductive tissue and disease and began developing patient-derived models of the endometrium. I established a relationship between endometriosis lesions, nerves and pain and how this interaction was mediated by inflammation. I further developed patient-derived in vitro models to understand the interaction between inflammation and hormonal response of endometriotic lesions and how this could be utilized to target current and novel treatments. On returning to Australia in 2016 I joined the Genomics of Reproductive Disorders laboratory to integrate genetic background into patient-derived in vitro models. I established the Endometriosis Research Queensland Study (ERQS) in collaboration with the Royal Brisbane and Women’s Hospital (RBWH) and extended in vitro models into complex multi-cellular assembloids (combinations of organoids and surrounding stromal cells).

Professor Mobli is a structural biologist and a group leader at the University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN). He is well known internationally for his contributions to the basic theory of multidimensional nuclear magnetic resonance and its applications to resolving the molecular structure of peptides and proteins, as well as studying their physiochemical properties and function. Mehdi's contributions to the field has been recognised by being appointed an Executive Editor of the AMPERE society's journal "Magnetic Resonance", and to the advisory board of the international Biological Magnetic Resonance Data Bank (BMRB) as well as serving on the board of directors of the Australia and New Zealand Society for Magnetic Resonance (ANZMAG). He is a former ARC Future Fellow and recipient of the ASBMB MERCK medal, the Australia Peptide Society's Tregear Award, the ANZMAG Sir Paul Callaghan medal and the Lorne Proteins Young Investigator Award (now Robin Anders Award).

Prof. Mobli's research group focuses on characterising the structure and function of receptors involved in neuronal signalling, with a particular focus on developing new approaches for the discovery and characterisation of modulators of these receptors through innovations in bioinformatics, biochemistry and and biophysics. This work has led to publication of more than 100 research articles attracting over 6,000 citations.

Associate Professor Muttenthaler is a medicinal chemist working at the interface of chemistry and biology with a strong passion for translational research. His research focuses on bioactive peptides and exploring Nature's biodiversity to develop advanced molecular tools, diagnostics, and therapeutics. His background in drug discovery and development, as well as his interdisciplinary training in the fields of chemistry, molecular biology and pharmacology, assist him in characterising these often highly potent and selective compounds to study their interactions with human physiology for medical innovations in pain, cancer, gut disorders and neurological diseases.

Dr Dominic Ng graduated with a BSc (Hons) and gained his PhD from the University of Western Australia. His doctoral studies, conducted in the laboratory of Assoc. Prof. Marie Bogoyevitch, were focused on cardiomyocyte signalling mechanisms regulating pathological tissue growth (ie cardiac hypertrophy). He continued his research training in Singapore as a post-doctoral research fellow based at the Institute of Molecular and Cell Biology, the flagship institute of Singapore’s science agency (A*STAR) located at the world renowned Biopolis research precinct. During this time, his research interests turned to the complex regulation of the cytoskeleton and their functions in development and disease.

He returned to the Australian medical research community on an NHMRC Peter Doherty Fellowship (2006-2010) followed by a Faculty Trust Roper Fellowship (2011-2012). In this time, Dominic established an independent research program focused on complex signalling regulation of microtubule organization. In 2013, Dominic was appointed as a Senior Research Fellow, supported by an ARC Future Fellowship (2013-2016) at the Department of Biochemistry within the Bio21 Institute, University of Melbourne. In 2015, Dominic relocated his research group to the School of Biomedical Science, University of Queensland and is currently appointed as an ARC Future Fellow and Senior Lecturer.

I completed my PhD in Neuroscience at UQ in 2009. After this, I undertook postdoctoral training in motor neuron disease/amyotrophic lateral sclerosis (MND/ALS) under the mentorship of neurologists at Royal Brisbane & Women's Hospital. In 2012, I received a MND Research Australia Bill Gole Fellowship to develop a research focus to study metabolic dysfunction in MND/ALS. I started my independent research group at UQ in 2015, after receiving the Scott Sullivan MND Research Fellowship to lead a translational program to define the contribution of altered metabolic homeostasis to MND/ALS pathophysiology. In 2017, I relocated my laboratory to the Australian Institute for Bioengineering and Nanotechnology to introduce the use of human stem cells for disease modelling into my reserach program. In 2020, I was awarded a FightMND Mid-Career Research Fellowship to transition into clinical trials.

My current research integrates studies in MND/ALS patients with studies in human-derived cell models (stem cell-derived neurons, human primary myosatellite cells, human myotubes) and mouse models of MND/ALS. I have served as lead investigator or co-investigator on several projects aimed at defining the mechanisms that drive MND/ALS and identifying therapeutic strategies for the disease. Projects have led to the expediting of clinical trials (NCT03506425; NCT04788745, NCT05959850). In 2021, I established the MND at UQ Collective to enhance national and international collaboration, and to facilitate community consultation to drive scientific and clinical discoveries in ALS and FTD (www.uq.edu.au/mnd-collective).

I have received invitations to contribute to high impact review articles (i.e., Brain, Nat Rev Neurol), and have received >20 invitations to speak at conferences including: 33rd International ALS/MND Symposium (2022, Plenary), 64th Japanese Society of Neurology Meeting (2023, Tokyo; Plenary), 3rd International Pan-Asian Consortium for Treatment and Research in ALS (PACTALS) Congress (2023, Kuala Lumpur), 18th International Congress on Neuromuscular Diseases (2024, Perth).

Dr Quan Nguyen is a Group Leader at the Institute for Molecular Bioscience (IMB), The University of Queensland. He is leading the Genomics and Machine Learning (GML) lab to study neuroinflammation and cancer-immune cells at single-cell resolution and within spatial morphological tissue context. His research interest is about revealing gene and cell regulators that determine the states of the complex cancer and neuronal ecosystems. Particularly, he is interested in quantifying cellular diversity and the dynamics of cell-cell interactions within the tissues to find ways to improve cancer diagnosis or cell-type specific treatments or the immunoinflammation responses that cause neuronal disease.

Using machine learning and genomic approaches, his group are integrating single-cell spatiotemporal sequencing data with tissue imaging data to find causal links between cellular genotypes, tissue microenvironment, and disease phenotypes. GML lab is also developing experimental technologies that enable large-scale profiling of spatial gene and protein expression (spatial omics) in a range of cancer tissues (focusing on brain and skin cancer) and in mouse brain and spinal cord.

Dr Quan Nguyen completed a PhD in Bioengineering at the University of Queensland in 2013, postdoctoral training in Bioinformatics at RIKEN institute in Japan in 2015, a CSIRO Office of Chief Executive (OCE) Research Fellowship in 2016, an IMB Fellow in 2018, an Australian Research Council DECRA fellowship (2019-2021), and is currently a National Health and Medical Research Council leadership fellow (EL2). He has published in top-tier journals, including Cell, Cell Stem Cell, Nature Methods, Nature Protocols, Nature Communications, Genome Research, Genome Biology and a prize-winning paper in GigaScience. In the past three years, he has contributed to the development of x8 open-source software, x2 web applications, and x4 databases for analysis of single-cell data and spatial transcriptomics. He is looking for enthusiastic research students and research staff to join his group.

Dr Marloes Dekker Nitert is an Associate Professor at The University of Queensland. Marloes is a biomedical researcher with a PhD from Lund University in Sweden. Her research focuses on the role of metabolism in complications of pregnancy. She currently heads a laboratory research group at the School of Chemistry and Molecular Biosciences studying the role of metabolism in pregnancy complications and especially how the gut microbiome contributes to a healthy pregnancy and to pregnancy complications. Marloes works closely together with clinician-scientists and clinicians at the Royal Brisbane and Women’s Hospital and the Mater Mothers' Hospital to do her translational research. Marloes is a board member of the Australian Society for Medical Research and a past Council member of the Society of Obstetric Medicine Australia and New Zealand.

Megan O’Mara is a Professor and Group Leader at the Australian Institute for Bioengineering and Nanotechnology (AIBN), UQ. Her group uses multiscale modelling techniques to understand how changes in the biochemical environment of the cell membranes alters membrane properties and modulates the function of membrane proteins. She has research interests in multidrug resistance, computational drug design and delivery, biopolymers, and personalized medicine. Megan completed her PhD in biophysics at the Australian National University in 2005 before moving to the University of Calgary, Canada, to take up a Canadian Institutes of Health Research Postdoctoral Fellowship. In 2009, she returned to Australia to join University of Queensland’s School of Chemistry and Molecular Biosciences as a UQ Postdoctoral Fellow, before commencing an ARC DECRA in 2012 where she continued her computational work on membrane protein dynamics. In 2015, Megan joined the Research School of Chemistry, Australian National University in 2015 as Rita Cornforth Fellow and Senior Lecturer. In 2019 she was promoted to Associate Professor and was Associate Director (Education) of the Research School of Chemistry ANU in 2019-2021. In April 2022 she relocated to AIBN.

I studied Technical Mathematics at the Vienna University of Technology. I also earned a Master's degree in Law and I finished the first ("non-clinical") part of Medical Studies at the University of Vienna. I earned my PhD in Applied Mathematics at the University of Vienna in 2007. My PhD advisor was Christian Schmeiser, my co-advisor was Peter Markowich. I spent several months at the University of Buenos Aires working with C. Lederman and at the ENS-Paris rue d'Ulm in the group of B. Perthame.

Before coming to UQ, I held post-doc positions at the Wolfgang Pauli Insitute (Vienna), University of Vienna and the Austrian Academy of Sciences (RICAM). In 2013 I won an Erwin Schrödinger Fellowship of the Austrian Science Fund (FWF). I was a post-doc researcher in the group of Alex Mogilner first at UC Davis, then at the Courant Institute of Math. Sciences (New York University).

I moved to UQ in Dec. 2016. More recently, in 2024, I spent 4 months at the department of Mathemetics of the U. of Heidelberg as a visiting scientist.

Biography

Dr Huadong Peng is a Group Leader and Senior Research Fellow at the UQ's Biosustainability Hub, Australian Institute for Bioengineering and Nanotechnology (AIBN), UQ. He is a Future Academic Leader in the Australia’s Food and Beverage Accelerator (FaBA), and part of ARC Centre of Excellence in Synthetic Biology (CoESB). He earned his PhD from Monash University in Nov 2018, followed by postdoctoral training at Imperial College London and the Technical University of Denmark until Dec 2023. Prior to his PhD, he received his Master Degree from the University of Chinese Academy of Sciences in 2013 and a Bachelor Degree from China Three Gorges University in 2010. Additionally, he worked as a research associate at Novozymes (now Novonesis) from Nov 2013 to Jan 2015.

Since Jan 2024, Dr Peng has led the Yeast Engineering and Synthetic Biology (YESBio) research group (10-15 members), focusing on sustainable biomanufacturing. His research interests include 1) developing innovative synthetic biology tools, such as gene assembly methods, CRISPR-based genome editing tools, and biosensors; 2) modular metabolic engineering for advanced microbial cell factories, 3) synthetic microbial communities and 4) emerging Bio+ enabling technologies for applications in food ingredients, biochemicals, biofuels, and biomedicines.

Dr Peng secured $4.8M funding as Chief Investigator ($2.1M to his team), including the prestigious Marie Skłodowska-Curie Fellowship. He has published 40+ peer-reviewed papers in prestigious journals, including Nature Microbiology, Nature Chemical Biology, Nature Communications. He actively contributes to the scientific community through editorial roles, including Associate Editor for Frontiers in Bioengineering and Biotechnology and Youth Editor for The Innovation (IF 26), BioDesign Research and mLife. He is also an invited peer reviewer for 30+ international journals and grants such as Nature Synthesis, ACS Synthetic Biology, etc.

Dr Peng is looking for highly motivated Honours, Master and PhD students, and highly competitive full scholarship may be provided. The University of Queensland ranks in the top 50 as measured by the Performance Ranking of Scientific Papers for World Universities. The University also ranks 45 in the QS World University Rankings, 52 in the US News Best Global Universities Rankings, 60 in the Times Higher Education World University Rankings and 55 in the Academic Ranking of World Universities.

Industry

Dr Peng is keen to translate the technologies developed by his team into real-world commercial applications, including advanced microbial cell factories, synthetic microbial communities, and optimised bioprocesses. These innovations enable the delivery of sustainable bio-solutions for industrial sectors spanning agri-food, industrial biotechnology and human health. He has established close collaborations with industry partners such as Woodside Energy, Noumi Operations, and Cauldron Fermentation, and he is actively engaging with additional partners, including Levur and NeweraBio.

Dr Peng has experience consulting with multiple companies and is open to taking on casual consulting roles as opportunities arise.

Selected Funding & Awards

Dr Peng has secured $4.8M funding as Chief Investigator ($2.1M to his team), including

• 2025 Australia’s Food and Beverage Accelerator (FaBA)-Cauldron ferm, $2M, CIB
• 2025 Australia’s Food and Beverage Accelerator (FaBA)-Noumi Operations, $2M, co-CIA
• 2025 NCRIS Synthetic Biology Voucher Scheme, $40K, CIA
• 2024 UQ Biosustainability hub seed funding, $50K, CIA
• 2024 Australia’s Food and Beverage Accelerator seed funding, $160K, CIA
• 2023 Chinese Government Award for Outstanding Self-financed Students Abroad, $15K
• 2022 Marie Skłodowska-Curie Fellowship ($266K, 8% success rate)

Key Publications (#, co-first author; *, corresponding author)

1. Chen, H.#, Peng, H.#, Ellis, T., & Ledesma-Amaro, R. Programmable cell–cell adhesion in synthetic yeast communities for improved bioproduction. Nature Chemical Biology 2026. https://doi.org/10.1038/s41589-025-02081-1
2. Peng, H.; Darlington, A. P. S.; South, E. J.; Chen, H.-H.; Jiang, W.; Ledesma-Amaro, R*. A molecular toolkit of cross-feeding strains for engineering synthetic yeast communities. Nature Microbiology 2024. 9(3), 848-863.
3. Park Y.-K., Peng H, Hapeta P., Sellés Vidal L. and Ledesma-Amaro R*. Engineered cross-feeding creates inter- and intra-species synthetic yeast communities with enhanced bioproduction. Nature Communications 2024, 15(1): 8924.
4. Aulakh S#, Vidal L#, South E#, Peng H, Varma S, Herrera-Dominguez L, Ralser M*, Ledesma-Amaro R*. Spontaneously establishing syntrophic yeast communities improves biosynthetic yield through shared labour. Nature Chemical Biology 2023, 19(8), 951-961.
5. Jiang W, Hernández V-D, Peng H, Liu L, Haritos VS, Ledesma-Amaro R* Metabolic engineering strategies to enable microbial utilization of C1 feedstocks. Nature Chemical Biology 2021, 17(8), 845-855. `
6. P Gao, Sun H., Ledesma-Amaro R., Marcellin E. and Peng H.* Advancements and Challenges in the Bioproduction of Raspberry Ketone by Precision Fermentation. Future Foods 2025: 100606.
7. Wen, Q., Xu, X., He, Q., Wang, C., Chen, Z., Zhong, W., Peng, H.*, Yang, M.*, & Xing, J*. Dual-pathway engineering enables robust vanillin bioproduction in Pseudomonas putida. Chemical Engineering Journal 2025, 526.
8. Peng, H.*; Chen, R.; Shaw, W. M.; Hapeta, P.; Jiang, W.; Bell, D. J.; Ellis, T.; Ledesma-Amaro, R*. Modular Metabolic Engineering and Synthetic Coculture Strategies for the Production of Aromatic Compounds in Yeast. ACS Synthetic Biology 2023, 12 (6), 1739-1749.
9. Peng, H.; He, L.; Haritos, V. S*. Flow-cytometry-based physiological characterisation and transcriptome analyses reveal a mechanism for reduced cell viability in yeast engineered for increased lipid content. Biotechnology for Biofuels 2019, 12 (1), 98.
10. Peng, H.; Chen, H.; Qu, Y.; Li, H.; Xu, J*. Bioconversion of different sizes of microcrystalline cellulose pretreated by microwave irradiation with/without NaOH. Applied Energy 2014, 117 (0), 142-148

Updated on 2 Jan 2026

Dr Giovanni Pietrogrande is based at the Australian Institute for Bioengineering and Nanotechnology (AIBN), where he is the Synthetic Neuroimmunology Theme Leader.

He leads the development of advanced human brain and spinal cord organoid models to study neuroinflammation, demyelination and neurodegeneration, with a particular focus on how microglia, oligodendrocytes and other neural cells interact to drive diseases such as multiple sclerosis and motor neuron disease, and on using this knowledge to identify and test new therapeutic strategies. His research program is supported by competitive funding from HNMRC, MS Australia, MND Research Australia and FightMND, underscoring the translational impact and clinical relevance of his work.

Together with his team, he works on a broad range of problems, from engineering next-generation immune-based cell therapies and endowing central nervous system organoids with a functional immune system, to modelling their interactions with immune cells to fully reproduce neurodegenerative and neuroinflammatory pathologies. The group also leverages synthetic biology to design new strategies to rebalance neuroinflammation, promote remyelination and repair neural circuits.

I received my Bachelor's in Biology (2001) from Yarmouk University in Jordan, followed by postgraduate degrees from the University of Houston in Houston-Texas (2002-2007). My studies are integrative in nature, joining the best of both the Neuroscience world and Circadian Biology (the study of biological clocks). In the laboratory of Prof. Arnold Eskin, I investigated how processes as complex as learning and memory are modulated by biological clocks i.e. the circadian (about 24 hours) system, using Aplysia californica as the experimental model. After completing my Master's in Science in 2005, my research focused on the mechanism by which biological clocks modulate learning and memory. This work was performed in the laboratories of Prof. Gregg Cahill and Prof. Greg Roman, experts in chronobiology and behavioral neuroscience, respectively. Using Zebrafish as a model system, I investigated the role of melatonin, a night-time restricted hormonal signal, in modulating long-term memory consolidation. My findings, published in Science in 2007, shows that the circadian system via the cyclic night-time confined synthesis/release of melatonin “the hormone of darkness” functions as a modulator, shaping daily variations in the efficiency by which memories are processed. After receiving my Ph.D. in 2007, I joined as a postdoctoral fellow the laboratory of the pharmacologist and melatonin researcher Prof. Margarita Dubocovich. My postdoctoral work engaged in elucidating the role of melatonin in circadian physiology and pharmacology during development and ageing in rodents (Mus musculus) and non-human primates (Macaca mulatta) at the Feinberg School of Medicine (Northwestern University-Chicago) and the State University of New York (SUNY). From 2010-2015, I held a teaching/research position in the Dr. Senckenbergische Anatomy and the Dept. of Neurology at the Goethe University in Frankfurt-Germany. During this time, I was involved in teaching gross human anatomy while continuing my endeavor in understanding the mechanistics involved in shaping memory processes (acquisition, consolidation and retrieval) by the circadian system.

I am an early career neuroscientist investigating the capacity for neural progenitor cell behaviour to shape neural circuit formation, maintenance and function during development and throughout adulthood. More specifically, the role of oligodendrocyte progenitors and myelin in brain circuit formation and maintenance. My research examines the brain under health and pathological conditions by performing manipulations relevant to autism spectrum disorder, multiple sclerosis and schizophrenia. While under the supervision of Prof Helen Cooper at the Queensland Brain Institute – University of Queensland - I studied how the WRC-Cyfip1-FMRP protein network impaired apical radial glial progenitor function and neural migration, leading to cortical malformation and Autism-like traits in mice. During my PhD at University of Tasmania and under the supervision of Prof Kaylene Young, I studied the effect of neuronal activity on cells of the oligodendrocyte lineage. I found that voltage-gated calcium channels are critical for oligodendrocyte progenitor cell survival and characterised the impact of kainite receptor dysfunction on neuropathology and behaviour in mice. Currently under the supervision of Dr Carlie Cullen I am using transgenic mice strategies to determine how aberrant myelination can contribute to onset of neuropsychiatric and neurodegenerative disorders. I am also using mouse models of demyelination to investigate the effect of infectious diseases such as COVID19 and influenza on oligodendrocyte lineage cell function and the impact for myelin repair and multiple sclerosis disease progression. I have a long-standing interest in neuroscience research, that extends from understanding how brain function is regulated during development and in healthy ageing, and the dysregulated signalling pathways that enable neurodevelopmental and neurodegenerative disorders.

Dr Melanie Robitaille is a Senior Post-Doctoral Researcher working with the Calcium Signalling in Therapeutics Team (CaSTT) in the School of Pharmacy. This team specializes in the development and application of novel methodologies and cellular assays in drug discovery, including the use of genetically encoded indicator for high-content imaging in live cells.

Her interests are to elucidate how calcium signals are remodelled in disease states, to identify calcium transporters as new therapeutic targets and to develop molecular and cellular screening tools to be used in drug development programs. She has an established profile in cellular and molecular biology, with high expertise in plasmid cloning, lentiviral transduction and the use of CRISPR/Cas9 to modulate gene expression.

Professor Eugeni Roura is a nutritionist with interests in digestive physiology and gut health, chemosensory science (including taste and smell) and transgenerational mechanisms relevant to chickens, pigs and humans. Eugeni holds a Veterinary and PhD degrees from the Autonomous University of Barcelona and a MPhil and post-doctoral appointments at the University of California (Davis). He developed a sixteen-year career in the feed and food industries before joining The University of Queensland (2010) where he currently leads the Nutrition & Chemosensory Science Group. The main current research areas in animal science include appetite modulation in chickens and pigs, nutrition interventions to boost embryonic/foetal development (including “in ovo”), and strategies to improve sustainability of chicken meat, egg and pork production. In human nutrition the focus is around food allergies and appendicitis. In 2011, Eugeni joined the UQ School of Biomedical Sciences as an Affiliated Lecturer. Since 2010 he has graduated 20 PhD students in Australia, published more than 100 peer-reviewed publications, and has been invited as keynote speaker to more than 50 national and international scientific meetings. He is currently serving as President of the World’s Poultry Science Association (Australia branch), Director of the AgriFutures Chicken Meat Consortium, and member of the National Committee for Nutrition (Australian Academy of Sciences), R&D and Education Committees of the Australasian Pork Research Institute Ltd., and the Federation of Oceania Nutrition Societies. He was the recipient of the Nutrition Society of Australia 2024 Medal award.

I am Professor, NHMRC Investigator Fellow (EL2) and group leader (Exosome Biology Laboratory) at UQ Centre for Clinical Research. I am nationally and internationally (>20 invitations to international meetings in the last 5 years) acknowledged key opinion leader on Extracellular Vesicle (rated 3th worldwide (Top 0.015%) and 1st in Australia in expertise for “Extracellular Vesicles and Exosomes” on Expertscape) and biomarker discovery (140 publications, and >8000 citations in the last 7 year). I have made a major conceptual contribution to EV biology with diagnostic and therapeutic implications. In the last 8 years, my primary research and commercialisation activities have focused on the identification and validation of biomarkers, and development of In Vitro Multivariate Index Assays for clinically relevant complications (including ovarian cancers, and obstetrical syndromes) and their translation into clinical applications. In Academia, I have pursued these objectives through the development and leadership of clinical translation research teams and facilities, both in Australia and overseas. For example, I had a leadership role in established the Centre for Clinical Diagnostics (CCD). Within the UQCCR, I established an exosome research team to evaluate the clinical utility of extracellular vesicles as liquid biopsies, IVDs and therapeutics. Much of our effort in this field of endeavour has involved optimising isolation methods for extracellular vesicles and their analytical analysis - including the use of protein solution array (e.g. Luminex), mass spectrometry profiling (using MS/MS SWATH) and more recently miRNA analysis.